MedTrace Logo

Clinical Trials

NCT03047213 | ACTIVE_NOT_RECRUITING | PHASE2
17 participants

Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-31
Start Date:
2017-08-24
Completion:
2020-10-06
Conditions
  • Locally Advanced Bladder Urothelial Carcinoma
  • Metastatic Transitional Cell Carcinoma
  • Metastatic Urothelial Carcinoma
  • Recurrent Bladder Carcinoma
  • Stage III Bladder Urothelial Carcinoma AJCC v6 and v7
  • Stage IV Bladder Urothelial Carcinoma AJCC v7
Interventions
  • DRUG
Results Available
NCT03011814 | RECRUITING | PHASE1/PHASE2
78 participants

Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-31
Start Date:
2017-03-08
Completion:
2030-04-14
Conditions
  • Folliculotropic Mycosis Fungoides
  • Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma
  • Recurrent Mycosis Fungoides
  • Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma
  • Refractory Mycosis Fungoides
  • Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified
  • Sezary Syndrome
  • Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma
Interventions
  • BIOLOGICAL
  • OTHER
  • DRUG
No Results Yet
NCT02954874 | ACTIVE_NOT_RECRUITING | PHASE3
1155 participants

Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-31
Start Date:
2017-01-18
Completion:
2026-08-31
Conditions
  • Breast Carcinoma In Situ
  • Invasive Breast Carcinoma
  • Stage I Breast Cancer AJCC v7
  • Stage II Breast Cancer AJCC v6 and v7
  • Stage III Breast Cancer AJCC v7
  • Triple-Negative Breast Carcinoma
Interventions
  • PROCEDURE
  • OTHER
  • BIOLOGICAL
  • RADIATION
No Results Yet
NCT02893917 | ACTIVE_NOT_RECRUITING | PHASE2
90 participants

Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-31
Start Date:
2017-08-11
Completion:
2023-03-14
Conditions
  • Advanced Prostate Adenocarcinoma With Neuroendocrine Differentiation
  • Castration-Resistant Prostate Carcinoma
  • Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation
  • Metastatic Prostate Carcinoma
  • Prostate Adenocarcinoma With Neuroendocrine Differentiation
  • Stage IV Prostate Adenocarcinoma AJCC v7
Interventions
  • DRUG
Results Available
NCT02888743 | ACTIVE_NOT_RECRUITING | PHASE2
110 participants

Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-31
Start Date:
2017-08-14
Completion:
2023-12-31
Conditions
  • Metastatic Colorectal Carcinoma
  • Metastatic Lung Non-Small Cell Carcinoma
  • Stage IV Colorectal Cancer AJCC v7
  • Stage IV Lung Non-Small Cell Cancer AJCC v7
  • Stage IVA Colorectal Cancer AJCC v7
  • Stage IVB Colorectal Cancer AJCC v7
Interventions
  • BIOLOGICAL
  • RADIATION
Results Available
NCT02883062 | ACTIVE_NOT_RECRUITING | PHASE2
67 participants

Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-31
Start Date:
2017-08-02
Completion:
2019-12-18
Conditions
  • Invasive Breast Carcinoma
  • Stage II Breast Cancer AJCC v6 and v7
  • Stage III Breast Cancer AJCC v7
  • Triple-Negative Breast Carcinoma
Interventions
  • DRUG
  • PROCEDURE
Results Available
NCT02627443 | ACTIVE_NOT_RECRUITING | PHASE1
35 participants

Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-31
Start Date:
2017-05-16
Completion:
2024-10-04
Conditions
  • Metastatic Fallopian Tube Carcinoma
  • Metastatic Ovarian Carcinoma
  • Metastatic Primary Peritoneal Carcinoma
  • Ovarian Endometrioid Tumor
  • Ovarian High Grade Serous Adenocarcinoma
  • Platinum-Sensitive Ovarian Carcinoma
  • Recurrent Fallopian Tube Carcinoma
  • Recurrent Ovarian Carcinoma
  • Recurrent Primary Peritoneal Carcinoma
  • Stage IV Fallopian Tube Cancer AJCC v6 and v7
  • Stage IV Ovarian Cancer AJCC v6 and v7
  • Stage IV Primary Peritoneal Cancer AJCC v7
Interventions
  • DRUG
  • OTHER
Results Available
NCT02595931 | ACTIVE_NOT_RECRUITING | PHASE1
66 participants

M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-31
Start Date:
2016-07-22
Completion:
2023-03-07
Conditions
  • Metastatic Colorectal Carcinoma
  • Metastatic Lung Small Cell Carcinoma
  • Metastatic Malignant Solid Neoplasm
  • Metastatic Pancreatic Carcinoma
  • Refractory Colorectal Carcinoma
  • Refractory Lung Small Cell Carcinoma
  • Refractory Malignant Solid Neoplasm
  • Refractory Pancreatic Carcinoma
  • Stage III Colorectal Cancer AJCC v8
  • Stage III Lung Cancer AJCC v8
  • Stage III Pancreatic Cancer AJCC v8
  • Stage IV Colorectal Cancer AJCC v8
  • Stage IV Lung Cancer AJCC v8
  • Stage IV Pancreatic Cancer AJCC v8
  • Unresectable Colorectal Carcinoma
  • Unresectable Lung Small Cell Carcinoma
  • Unresectable Malignant Solid Neoplasm
  • Unresectable Pancreatic Carcinoma
Interventions
  • DRUG
  • PROCEDURE
No Results Yet
NCT02595879 | ACTIVE_NOT_RECRUITING | PHASE1
21 participants

Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-31
Start Date:
2019-09-18
Completion:
2023-06-04
Conditions
  • Advanced Cervical Adenocarcinoma
  • Advanced Cervical Adenosquamous Carcinoma
  • Advanced Cervical Squamous Cell Carcinoma
  • Advanced Vaginal Adenocarcinoma
  • Advanced Vaginal Adenosquamous Carcinoma
  • Advanced Vaginal Squamous Cell Carcinoma
  • Stage IB2 Cervical Cancer AJCC v6 and v7
  • Stage II Cervical Cancer AJCC v7
  • Stage II Vaginal Cancer AJCC v6 and v7
  • Stage III Vaginal Cancer AJCC v6 and v7
  • Stage IIIB Cervical Cancer AJCC v6 and v7
  • Stage IVA Cervical Cancer AJCC v6 and v7
  • Stage IVA Vaginal Cancer AJCC v6 and v7
Interventions
  • PROCEDURE
  • DRUG
  • RADIATION
  • OTHER
Results Available
NCT02567435 | ACTIVE_NOT_RECRUITING | PHASE3
325 participants

Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-31
Start Date:
2016-06-01
Completion:
2023-06-30
Conditions
  • Alveolar Rhabdomyosarcoma
  • Botryoid-Type Embryonal Rhabdomyosarcoma
  • Embryonal Rhabdomyosarcoma
  • Rhabdomyosarcoma
  • Sclerosing Rhabdomyosarcoma
  • Spindle Cell Rhabdomyosarcoma
Interventions
  • OTHER
  • RADIATION
  • DRUG
  • BIOLOGICAL
Results Available
NCT02567422 | ACTIVE_NOT_RECRUITING | PHASE1
43 participants

Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-31
Start Date:
2017-04-17
Completion:
2023-12-31
Conditions
  • Head and Neck Carcinoma of Unknown Primary
  • Head and Neck Squamous Cell Carcinoma
  • Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7
  • Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7
  • Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7
  • Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7
  • Stage III Sinonasal Squamous Cell Carcinoma AJCC v6 and v7
  • Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7
  • Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7
  • Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7
  • Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7
  • Stage IV Sinonasal Squamous Cell Carcinoma AJCC v7
Interventions
  • DRUG
  • PROCEDURE
  • OTHER
  • RADIATION
Results Available
NCT02535312 | ACTIVE_NOT_RECRUITING | PHASE1/PHASE2
30 participants

Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-31
Start Date:
2016-03-08
Completion:
2022-12-31
Conditions
  • Advanced Malignant Solid Neoplasm
  • Advanced Peritoneal Malignant Mesothelioma
  • Advanced Pleural Malignant Mesothelioma
  • Recurrent Peritoneal Malignant Mesothelioma
  • Recurrent Pleural Malignant Mesothelioma
  • Refractory Malignant Solid Neoplasm
  • Unresectable Solid Neoplasm
Interventions
  • DRUG
Results Available
NCT02496663 | ACTIVE_NOT_RECRUITING | PHASE1
138 participants

Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-31
Start Date:
2016-05-11
Completion:
2027-06-30
Conditions
  • Metastatic Lung Non-Small Cell Carcinoma
  • Recurrent Lung Non-Small Cell Carcinoma
  • Stage IV Lung Cancer AJCC v8
Interventions
  • PROCEDURE
  • BIOLOGICAL
  • DRUG
No Results Yet
NCT02453620 | ACTIVE_NOT_RECRUITING | PHASE1
57 participants

Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-31
Start Date:
2016-02-12
Completion:
2021-04-22
Conditions
  • Anatomic Stage III Breast Cancer AJCC v8
  • Anatomic Stage IV Breast Cancer AJCC v8
  • Breast Adenocarcinoma
  • Invasive Breast Carcinoma
  • Malignant Solid Neoplasm
Interventions
  • PROCEDURE
  • OTHER
  • DRUG
  • BIOLOGICAL
No Results Yet
NCT02446600 | ACTIVE_NOT_RECRUITING | PHASE3
579 participants

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-31
Start Date:
2016-03-28
Completion:
2020-02-23
Conditions
  • Fallopian Tube Clear Cell Adenocarcinoma
  • Fallopian Tube Transitional Cell Carcinoma
  • Fallopian Tube Undifferentiated Carcinoma
  • Ovarian Clear Cell Adenocarcinoma
  • Ovarian Endometrioid Tumor
  • Ovarian Seromucinous Carcinoma
  • Ovarian Serous Tumor
  • Ovarian Transitional Cell Carcinoma
  • Ovarian Undifferentiated Carcinoma
  • Recurrent Fallopian Tube Carcinoma
  • Recurrent Ovarian Carcinoma
  • Recurrent Ovarian Endometrioid Adenocarcinoma
  • Recurrent Primary Peritoneal Carcinoma
Interventions
  • PROCEDURE
  • DRUG
  • OTHER
Results Available
NCT02425345 | COMPLETED | NA
49331 participants

Women's Health Initiative Strong and Healthy Study

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-31
Start Date:
2015-04-02
Completion:
2024-12-31
Conditions
  • Myocardial Infarction
  • Stroke
  • Cardiovascular Mortality
  • Hip Fractures
  • Falls
  • Mortality
  • Venous Thromboembolic Event
  • Peripheral Artery Disease
  • Physical Function
  • Coronary Revascularization
  • Mobility and Independence
  • Clinical (Non-hip) Fractures
  • Sleep
  • Depressive Symptoms
Interventions
  • BEHAVIORAL
Results Available
NCT02345265 | ACTIVE_NOT_RECRUITING | PHASE2
70 participants

Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-31
Start Date:
2016-05-23
Completion:
2022-07-07
Conditions
  • Fallopian Tube Carcinoma
  • Fallopian Tube Endometrioid Adenocarcinoma
  • Fallopian Tube Serous Adenocarcinoma
  • Ovarian Carcinoma
  • Ovarian High Grade Endometrioid Adenocarcinoma
  • Ovarian High Grade Serous Adenocarcinoma
  • Primary Peritoneal Carcinoma
  • Primary Peritoneal Endometrioid Adenocarcinoma
  • Primary Peritoneal Serous Adenocarcinoma
Interventions
  • PROCEDURE
  • DRUG
  • OTHER
Results Available
NCT02101775 | ACTIVE_NOT_RECRUITING | PHASE2
124 participants

Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-31
Start Date:
2014-07-21
Completion:
2022-02-03
Conditions
  • Ovarian Brenner Tumor
  • Ovarian Clear Cell Cystadenocarcinoma
  • Ovarian Endometrioid Adenocarcinoma
  • Ovarian Malignant Mixed Mesodermal (Mullerian) Tumor
  • Ovarian Mucinous Cystadenocarcinoma
  • Ovarian Seromucinous Carcinoma
  • Ovarian Serous Cystadenocarcinoma
  • Ovarian Serous Surface Papillary Adenocarcinoma
  • Ovarian Undifferentiated Carcinoma
  • Recurrent Fallopian Tube Carcinoma
  • Recurrent Ovarian Carcinoma
  • Recurrent Primary Peritoneal Carcinoma
Interventions
  • DRUG
  • OTHER
Results Available
NCT01804686 | RECRUITING | PHASE3
700 participants

A Long-term Extension Study of PCI-32765 (Ibrutinib)

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-31
Start Date:
2013-09-09
Completion:
2026-12-31
Conditions
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Mantle Cell Lymphoma
  • Follicular Lymphoma
  • Diffuse Large B-cell Lymphoma
  • Waldenstrom Macroglobulinemia
  • Chronic Graft Versus Host Disease
Interventions
  • DRUG
No Results Yet
Previous
Sorted by latest updates
Next
Showing 40 trials per page